Glioblastoma Multiforme Global Market Report 2025

The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $2.5 billion in 2024 to $2.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period was driven by the increasing incidence of glioblastoma multiforme, advancements in healthcare infrastructure, greater awareness, improved access to advanced therapies, and a growing aging population.

The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The projected growth in the forecast period can be attributed to the rising cases of brain and other nervous system cancers, increased acceptance of surgical techniques, heightened awareness, early disease diagnosis, and a surge in research and development activities. Key trends expected in this period include advancements in medical technology, improvements in imaging techniques, the expansion of personalized medicine, the integration of AI for diagnosis, and ongoing technological and scientific developments.

The increasing number of brain disorder cases is expected to drive the growth of the glioblastoma multiforme market. Brain disorders affect the structure or function of the brain, leading to cognitive, emotional, or physical impairments. The rising prevalence of these conditions is attributed to factors such as aging populations, increased life expectancy, lifestyle changes, and advancements in diagnostic technology. Research into brain disorders contributes to a better understanding of glioblastoma multiforme (GBM), leading to improvements in early detection, innovative treatments, and enhanced patient outcomes. By studying neurological conditions, scientists can identify genetic and molecular factors that contribute to GBM development. For example, in February 2025, Dementia Australia reported that approximately 433,300 Australians are living with dementia, with this number projected to increase to 812,500 by 2054. Additionally, younger-onset dementia currently affects around 29,000 people, with estimates suggesting an increase to 41,000 by 2054. As brain disorder cases continue to rise, the glioblastoma multiforme market is expected to expand.

Leading companies in the glioblastoma multiforme market are focusing on developing advanced therapies, such as CAR T-cell therapies, to address the unmet medical needs of aggressive brain cancer. CAR T-cell therapy is a form of immunotherapy that modifies a patient's T-cells to target and destroy cancer cells more effectively. In June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, initiated a Phase IB clinical trial for CHM 1101 (CLXT CAR T) therapy in patients with recurrent or progressive glioblastoma multiforme (GBM). Conducted across multiple centers, the trial aims to assess the safety and efficacy of the therapy while determining the optimal Phase 2 dose. Early Phase 1a results demonstrated disease stability, and the new trial seeks to build on these findings to advance the therapy’s development. The company intends to use the trial data to design a registration study and obtain regulatory feedback.

In January 2022, ITM Isotope Technologies Munich SE (ITM), a Germany-based radiopharmaceutical biotech company, partnered with Helmholtz Center Munich to enhance treatment options for glioblastoma multiforme. This collaboration focuses on advancing the clinical development of targeted radiopharmaceutical therapy, addressing a critical need for effective treatments for this aggressive cancer. Helmholtz Center Munich, a Germany-based research institution, specializes in the development of immunotherapy for glioblastoma treatment.

Major players in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, and VBI Vaccines Inc.

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in glioblastoma multiforme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the glioblastoma multiforme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Glioblastoma multiforme (GBM) is a highly aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the most lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.

The primary drug classes used for glioblastoma multiforme treatment include chemotherapy agents such as temozolomide, carmustine, lomustine, and others. These chemotherapy agents work by targeting and disrupting cancer cell division, helping to control tumor growth and improve survival, often in combination with other treatments. Diagnosis is performed using various tools, including magnetic resonance imaging (MRI), computed tomography (CT) scans, biopsies, and others. Treatment options include surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field therapy, and more. The drugs and treatments are utilized by various end-users, including hospitals, cancer research institutes, and ambulatory surgical centers.

The glioblastoma multiforme market research report is one of a series of new reports that provides glioblastoma multiforme market statistics, including the glioblastoma multiforme industry global market size, regional shares, competitors with the glioblastoma multiforme market share, detailed glioblastoma multiforme market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme industry. This glioblastoma multiforme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glioblastoma multiforme market consists of revenues earned by entities by providing services such as palliative care, psychosocial support, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The glioblastoma multiforme market also includes sales of drugs, diagnostic tools, personalized medicine, and advanced drug delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.